Skip to main content

EXEL

Stock
Health Care
Biotechnology

Performance overview

EXEL Price
Price Chart

Forward-looking statistics

Beta
0.63
Risk
34.99%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Company info

SectorHealth Care
IndustryBiotechnology
Employees1K
Market cap$6.4B

Fundamentals

Enterprise value$11.2B
Revenue$2.3B
Revenue per employee—
Profit margin27.99%
Debt to equity8.78

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.19
Dividend per share—
Revenue per share$8.08
Avg trading volume (30 day)$126M
Avg trading volume (10 day)$182M
Put-call ratio—

Macro factor sensitivity

Growth+1.7
Credit+1.4
Liquidity+0.5
Inflation+0.6
Commodities+0.9
Interest Rates-1.2

Valuation

Dividend yield0.00%
PEG Ratio27.15
Price to sales5.47
P/E Ratio27.15
Enterprise Value to Revenue4.86
Price to book5.96

Upcoming events

Next earnings dayOctober 30, 2024
Next dividend day—
Ex. dividend day—

News

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research (July 21, 2025)
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research (July 21, 2025)
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research (July 10, 2025)
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

On Sunday, Exelixis, Inc. EXEL revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab.

Benzinga (June 23, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free